Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to find out why LLY stock is a Hold.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro ... most industries will need to reshore a lot of investment,” said Ricks, who attended last week ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Microsoft Corporation. Read 's Market Analysis on Investing.com ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.